

# Acta Radiologica

Draft Manuscript for Review

## **Diagnostic accuracy of simplified ultrasound hand examination protocols for detection of inflammation and disease burden in patients with rheumatoid arthritis.**

Journal:	<i>Acta Radiologica</i>
Manuscript ID	SRAD-2017-0419.R2
Manuscript Type:	Original Article
Keyword:	Ultrasound-Power Doppler < Modalities/Techniques, Hand < Structures, musculoskeletal ultrasound

SCHOLARONE™  
Manuscripts

Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Diagnostic accuracy of simplified ultrasound hand examination protocols for detection of inflammation and disease burden in patients with rheumatoid arthritis

### Abstract

**Background:** There is no consensus regarding the minimum of joints that should be included in an ultrasound (US) scoring system to reliably assess for disease activity in rheumatoid arthritis (RA).

**Purpose:** To assess whether simplified US protocols for hand examination are as informative as the examination of 22 joints in patients with RA, and to correlate the US parameters with disease activity (DAS-28).

**Material and Methods:** This is a cross-sectional study of 224 RA patients stratified based on their DAS-28 scores and assessed using eight preselected US examination protocols, including 22, 18, 16, 14, 10, 8 and two different combinations of 4 joints, respectively.

**Results:** We found a significant difference between different US hand scores regarding their ability to detect active inflammation and erosions. DAS-28 scores correlated very well with the Power Doppler (PD) scores generated by all eight US examination protocols ( $r=0.89-1$ ,

1  
2  
3 P<0.05), irrespective of patients' disease activity. Simplified US scores missed information  
4  
5 on presence of PD in 20.6 - 40.2% patients (P<0.05), and misdiagnosed non-erosive hand RA  
6  
7 in 12 - 38.4% patients (P<0.05), depending on the number of joints excluded from US hand  
8  
9 examination.  
10

11  
12 **Conclusion:** Preselected simplified US scores are less reliable in appreciating the disease  
13  
14 burden when compared with an extended protocol for 22 joint US examination, raising  
15  
16 clinicians' awareness regarding the need to comprehensively assess multiple hand joints to  
17  
18 reliably rule out subclinical inflammation.  
19

20  
21  
22 **Keywords:** hand, ultrasound, Power Doppler ultrasound.  
23  
24  
25  
26  
27

## 28 **Introduction**

29  
30  
31 RA is a chronic inflammatory condition associated with well-recognised inflammatory joint  
32  
33 features, which are amenable to US examination. The use of US facilitated a significant  
34  
35 progress in the early diagnosis of RA, enabling a better assessment of the disease activity,  
36  
37 prognosis and response to different therapeutic interventions. The implementation of US  
38  
39 scoring systems in addition to clinical examination could help standardising the way RA is  
40  
41 monitored; however, based on local availability of US and sonographer expertise, different  
42  
43 scoring systems have been used in clinical practice. Despite significant research progress in  
44  
45 supporting the role of US in RA, no consensus was reached with regard to what scoring  
46  
47 system is the most useful. The OMERACT US Task Force defined the US pathology  
48  
49 associated with RA (1), which combines tendon, joint and bone abnormalities (1, 2). The  
50  
51 presence of Power Doppler (PD) is recognized as a reliable objective measure of active joint  
52  
53 inflammation (3). Different semi-quantitative scoring systems are currently used for  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 assessing synovial hypertrophy (SH), joint effusion, tendon abnormalities and erosions (4),  
4  
5 and protocols for hand and feet US examination are well-established (5).  
6  
7

8 A recent systematic review of the scoring systems used to evaluate synovitis in RA found  
9  
10 difficult to determine the least number of joints that needed to be assessed for a global US  
11  
12 score (1). The purpose of our study was to investigate how much we can simplify the US  
13  
14 examination of hands in RA, without compromising the ability of a certain US scoring  
15  
16 system to evaluate the disease activity and damage associated with hand RA. The authors  
17  
18 focused on the US examination of hands as this is the most commonly used in routine clinical  
19  
20 practice.  
21  
22  
23  
24  
25  
26

## 27 **Material and Methods**

28  
29  
30 This is a real-life, cross-sectional study, which evaluated patients referred to our US  
31  
32 rheumatology outpatient clinics, presenting with inflammatory sounding hand joint pains.  
33  
34 The patients were referred based on clinician indication to have an US scan to help with  
35  
36 identifying joint inflammation that was not confidently assessed clinically. We examined 604  
37  
38 patients between Jan 2012 and August 2015. For each patient, a set of demographic, clinical  
39  
40 and laboratory data were recorded at the time of the scan. Of 604 patients referred to our  
41  
42 clinic, 224 patients with RA were included in the study analysis based on their final diagnosis  
43  
44 made using the 2010 ACR/EULAR classification criteria, following complete investigations  
45  
46 and revision of the clinical notes. Fig. 1 details the patient selection and stratification based  
47  
48 on DAS-28 scores.  
49  
50  
51  
52

53 This study evaluated the same set of reported outcomes and clinical and laboratory  
54  
55 parameters for all the patients, to ensure homogeneity of the collected data. The following  
56  
57 information was analyzed: disease duration (in months), hand tender joint count (TJC) and  
58  
59  
60

1  
2  
3 swollen joint count (SJC), as well as a patient reported global disease assessment score  
4  
5 (GVAS).  
6

7  
8 Additional data about the high sensitivity C-reactive protein (hsCRP), erythrocyte  
9  
10 sedimentation rate (ESR), presence of rheumatoid factor (RF), anti citrullinated cyclic  
11  
12 peptides antibodies (ACPA) and anti-nuclear antibodies (ANA) were collected at the time of  
13  
14 the scan (needed to exclude associated pathology).  
15

16  
17 For each patient, a detailed record was compiled of their medication at the time of the US  
18  
19 scan, including paracetamol and NSAIDs, disease-modifying drugs (DMARDs), biologic  
20  
21 therapies and glucocorticoids, either oral or intramuscular depot injection.  
22  
23

24  
25 The US protocol examination used included the extensor tendons and 22 joint assessments  
26  
27 (dorsal longitudinal and transverse views of wrists, including extensor tendons, metacarpophalangeal – MCP joints, and proximal interphalangeal – PIP joints), as per our local clinic  
28  
29 protocol. The same US examination protocol was used for each patient, irrespective of their  
30  
31 hand symptoms. The US findings were scored according to the OMERACT scoring system  
32  
33 (1). The hand US examination was performed by two clinicians (CC and LA) in the same  
34  
35 session, and for each patient a consensus was obtained.  
36  
37  
38

39  
40 We used a Logiq S8 US machine (GE Healthcare, Wauwatosa, Wisconsin, WI, USA),  
41  
42 equipped with a multi-frequency linear matrix array transducer (6-15 MHz). B-mode and PD  
43  
44 machine setting were optimized and standardized for all our patients' US examinations. The  
45  
46 settings used were: B-mode frequency 11-15 MHz depending on the depth of the anatomical  
47  
48 area, Doppler frequency 7.5-15, depending on the depth of anatomical area; Doppler gain 18-  
49  
50 20 dB, low wall filters and pulse repetition frequency around 800 Hz. In this study, we only  
51  
52 used Power Doppler (PD) mode.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The information collected comprised the following US parameters: SH grade (graded 1-3),  
4 erosions (present/absent), PD signal (graded 1-3), joint effusion (present/absent), osteophytes  
5 (present/absent), and tendon abnormalities (PD signal present/absent) using the US definition  
6 of joint pathology as defined by the OMERACT group (2) (Fig. 2 exemplifies two MCP  
7 joints with different SH and PD grades). Well controlled disease was defined as PD score  
8 zero (including joints and tendons).  
9

10  
11  
12 To address our research question and assess how many joints would require scanning, and  
13 which joints are most likely to provide the answer as to whether or not there is active disease,  
14 we tested and compared the following scoring systems (bilateral examination):  
15

- 16 - 22 joints (MCPs, PIPs, wrists)
- 17 - 18 joints (wrists, MCP 2-5 and PIP 2-5)
- 18 - 16 joints (MCP 2-5 and PIP 2-5)
- 19 - 14 joints (wrists, MCP 2-4 and PIP 2-4)
- 20 - 10 joints (wrists, MCP 2-3 and PIP 2-3)
- 21 - 8 joints (MCP 2-3 and PIP 2-3)
- 22 - 4 joints (wrists +MCP5)
- 23 - 4 joints (MCP 2-3)

24  
25  
26 The above joint combination score was selected based on our experience of performing US  
27 examination of hands in more than 1000 patients, which identified that the most affected  
28 joints in RA were the wrists, MCP 2,3 and 5, and PIP 2 and 3 (unpublished observation).  
29

30  
31  
32 The SH grade 1 score was calculated as the total number of the joints with SH grade 1, the  
33 SH grade 2 score as the total number of the joints with SH grade 2, and the SH grade 3 score  
34 as the total number of the joints with SH grade 3 per patient. The total PD score was the sum  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of all individual PD scores per patient, and the erosion score was calculated as the total  
4  
5 number of erosions per patient.  
6  
7

8 Data about active inflammation affecting tendons overlying the above mentioned joints were  
9  
10 also collected and reported separately. The total grey scale scores and PD scores for joints  
11  
12 were calculated as a sum of the individual scores for all the joints included in the US  
13  
14 examination protocol the score refers to. The duration of the US examination was  
15  
16 approximately 25 minutes/patient. This 22 joint protocol is used routinely in our US clinics,  
17  
18 which have 30 minute slots for clinical and US examination of patients with RA.  
19  
20

21  
22 Descriptive statistics were used to characterize the RA population, and Student T test, Mann-  
23  
24 Whitney U and Kuskal-Wallis tests were implemented for the assessment of different  
25  
26 parameters and US scoring systems (IBM SPSS Statistics 22, IBM Corporation, 1 New  
27  
28 Orchard Road, Armonk, New York 10504-1722, US). A P-value of <0.05 was considered a  
29  
30 statistically significant result. Spearman's correlation coefficients were used to correlate  
31  
32 permutations of pairs of US scores and the total PD scores with the disease activity, as  
33  
34 assessed by the disease activity score assessing 28 joints (DAS-28).  
35  
36

37  
38 The data were collected as standard of practice. The study analyzed cross-sectionally the  
39  
40 results of the US examinations of patients seen in our US clinics over a defined period of  
41  
42 time. No ethical approval or patient's consent were required as no patient information was  
43  
44 used for teaching or new intervention research. The results of our study analysis had no  
45  
46 impact on the clinical management of patients and their confidentiality was maintained.  
47  
48  
49  
50

## 51 52 53 **Results** 54 55 56 57 58 59 60

1  
2  
3 To characterize in detail our RA cohort, we stratified patients based on DAS-28 (ESR)  
4 assessment of disease activity (Table 1). Demographic parameters were similar among  
5 different disease activity groups. As expected, patients with higher disease activity scores had  
6 significantly higher TJC, SJC, ESR and GVAS, while the CRP levels were similar between  
7 different groups. Both objective and subjective parameters included in the DAS-28 composite  
8 score were significantly increased in patients with active disease compared to moderate or  
9 low disease activity groups and with the group in remission.  
10  
11

12  
13  
14  
15  
16  
17  
18  
19 There were no significant differences in the total US scores including the majority of US  
20 parameters, or in the disease duration or type of medication used (for both conventional and  
21 biologic DMARDs). The only significant difference was between the proportion of patients  
22 with SH grade 2 at the US examination of their hands, which was higher in patients with  
23 moderately-active and strongly-active RA ( $P<0.05$ ) (Table 1). The SH grade 2 total score also  
24 correlated with the SJC ( $r=0.89$ ,  $P<0.05$ ).  
25  
26  
27

28  
29  
30  
31  
32  
33 The comparative analyse of the above-mentioned US scores showed no significant  
34 differences between the ability of the pre-selected US scores to capture information regarding  
35 SH grade 2 and 3, and the total PD scores per patient; however, the proportion of patients  
36 with no active disease at the US examination differed significantly based on the number of  
37 joints included in the examination protocol ( $P<0.05$ ) (Table 2). Similarly, different US scores  
38 varied significantly in their ability to assess the total erosion score per patient and the  
39 proportion of patients with erosions ( $P<0.05$ ). By simplifying the US examination of the hand  
40 in RA patients, active RA was underdiagnosed in a proportion of 20.6 to 40.2% of patients;  
41 similarly, the erosive burden was underappreciated in 12 - 28.4% RA patients (Table 2).  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54 Strong correlations were found between the PD score generated by the 22 joint examination  
55 and all of the other US score combinations ( $r = 0.68 - 0.74$ ,  $P<0.05$ ). The scores that  
56  
57  
58  
59  
60



1  
2  
3 correlated very strongly were those assessing 8, 10 and 14 joints ( $r = 0.92-0.96$ ,  $P < 0.05$ ). The  
4  
5 weakest correlation was found between the 8 and the 4 joint score (wrist and MCP 5  
6  
7 bilaterally) ( $r = 0.28$ ,  $P < 0.05$ ) (Suppl. Table 1).  
8  
9

10 The permutation comparisons between pairs of US scores related to their ability to detect the  
11  
12 presence active joint inflammation found no significant differences between the total PD  
13  
14 scores assessed by 8, 10, 12 and 16 joint US scores and 10, 12, 16 and 18 joint scores,  
15  
16 respectively (Suppl. Table 2). Similarly, the total grey scale score (combining the total scores  
17  
18 for SH grade 2 and 3) identified no significant differences between the permutation  
19  
20 comparisons between the scores assessing 8, 10, 14, 16 and 18 joints (Suppl. Table 3).  
21  
22  
23

24 The analysis was also focused on correlating the total PD scores derived from all the pre-set  
25  
26 US examination protocols with the DAS-28 scores in patients stratified based on their disease  
27  
28 activity, to identify if certain US hand examination protocols can be used differentially in  
29  
30 patients with active disease compared to patients in remission. All the total PD scores derived  
31  
32 from the eight US examination protocols correlated very strongly with DAS-28 assessment,  
33  
34 irrespective of how well the disease was controlled ( $r = 0.88-1$ ,  $P < 0.005$ ).  
35  
36  
37  
38  
39  
40

## 41 Discussion

42  
43  
44 This is the first large cross-sectional study correlating different US examination protocols  
45  
46 (derived from a 22-hand joint comprehensive score) with DAS-28 score in patients in RA,  
47  
48 stratified based on their disease activity.  
49  
50

51 Quantitative and semi-quantitative US scores have been previously compared in RA (3), and  
52  
53 US examination have been found to be sensitive to therapeutic interventions (4-8). A  
54  
55 comprehensive study comparing several US score systems in RA found that all were sensitive  
56  
57  
58  
59  
60

1  
2  
3 to change when assessing the response of RA patients to adalimumab (9, 10). In addition,  
4  
5 simplified US scores (including 6 or 12 joints) have previously been compared with extensive  
6  
7 US protocol examinations (assessing 12, and 44 joints respectively), and showed good  
8  
9 sensitivity to change in three separate studies (11-13). However, none of these studies  
10  
11 stratified patients based on their disease activity scores or included RA patients based on the  
12  
13 clinical indication to have an US scan, as it is the case with our study. The need to use a  
14  
15 comprehensive US scoring system, capturing both active and chronic inflammatory changes  
16  
17 for assessment of RA disease activity, is supported by the good correlation between US and  
18  
19 MRI findings (8, 14). The presence of SH and PD signal was found to be associated with  
20  
21 structural damage in RA (15), even in patients in clinical remission (16), and was associated  
22  
23 with risk of flares (17, 18).  
24  
25  
26

27  
28 The role and reliability of US in the disease activity assessment in patients with RA is  
29  
30 supported by several studies (19-21).  
31  
32

33 Previous studies reported good correlation between hand US scores and DAS-28 assessment  
34  
35 using three different US scores (22, 23), result that was also replicated by our study, which  
36  
37 included a larger number of joint combinations, and also assessed US parameters stratified  
38  
39 based on the DAS-28 scores.  
40  
41

42 Our comparative analysis of several US scoring systems showed that there is significant  
43  
44 difference in terms of the equivalence of several US hand-scoring systems. Our study found  
45  
46 that age, duration of symptoms, duration of disease, type of medication and total PD score  
47  
48 generated by US examination of hands were not able to inform about the inclusion of patients  
49  
50 in one specific disease activity group, as patients stratified based on DAS 28 scores had  
51  
52 similar parameters.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In addition to previous studies, we have been interested in exploring the amount and  
4 significance of missed information related to the use of simplified US hand examination  
5 protocols. A significant proportion of patients have been diagnosed as having well-controlled  
6 or non-erosive hand RA by using US protocols limiting the number of joints examined (10.6 -  
7 40.2 % and 12-34.8%, respectively). Our study found that the assessment of our preselected  
8 8, 10 and 14 joints captured comparable amounts of information regarding disease activity in  
9 RA (still misdiagnosing around 40% of patients as having well controlled disease, equivalent  
10 to PD score zero), while the two 4 joint scores missed significant information when compared  
11 to the others (around 60% patient were diagnosed in remission despite having active disease  
12 at least in one joint). The scores including 20 and 22 joints captured more information than  
13 the 8, 10 and 14 joint scores, even if all the eight US scores we explored correlated very well  
14 with the DAS-28 assessment. This is particularly relevant for our patient group, characterized  
15 by a small number of active joints and clinical indication to have an US scan to establish if  
16 their disease was well controlled or not. In this context, underdiagnosing active disease would  
17 have erroneously led to classifying our patients as being in remission. The clinical consensus  
18 is that we cannot predict which joints are the most likely to flare in patients with RA patients;  
19 therefore examining only the joints that previously flared using a patient-tailored US protocol  
20 is not justified.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 Even if a comprehensive hand joint score is time-consuming, it can provide significant  
44 additional information compared to a simplified score, as our study showed. As expected, all  
45 the scores correlated very well with each other, because they are derived from a  
46 comprehensive US hand score, while missing significant information proportional to the  
47 number of joints excluded from US examination. All the pre-selected US hand scores  
48 correlated with the disease activity scores, despite the fact that the patient groups stratified  
49 based on disease activity had similar median total PD scores. This showed that subclinical in  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 inflammation can be found in similar proportion in RA patients, irrespective of their degree of  
4  
5 chronic joint changes that are likely to influence their DAS-28 score.  
6  
7

8 Limitations: Our study did not have strict inclusion criteria: the patients were included based  
9  
10 on clinical indication to exclude subclinical synovitis. Therefore, there is a significant  
11  
12 selection bias, as the study did not capture patients with obvious active synovitis detected by  
13  
14 clinical examination. In this particular clinical context, detection of active disease in at least  
15  
16 one joint is clinically relevant, as US examination triggered treatment optimization to  
17  
18 minimize joint damage (e.g. guided steroid injection targeting the active joints or escalation  
19  
20 of therapy). In conclusion, even if simplified US scores for hand assessment of RA disease  
21  
22 activity can be useful in practice, by examining additional joints, clinicians are able to detect  
23  
24 subclinical inflammation, which is not captured by the simplified US scores. If previously  
25  
26 studies re-assured clinicians that various US examination protocols correlated well with the  
27  
28 DAS-28 assessment or were sensitive to change following therapy, our study showed that a  
29  
30 significant proportion of patients can be misclassified as having well-controlled or non-  
31  
32 erosive disease as a result of simplified US protocols. Further studies, including large  
33  
34 longitudinal cohorts, are needed to establish the smaller number of joints needed to be  
35  
36 examined to minimize the risk of under detecting subclinical inflammation in patients with  
37  
38 hand RA.  
39  
40  
41  
42

43  
44 **Conflict of interest:**

45  
46  
47 The authors declared no conflicts of interest.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References:**

1. Mandl P, Naredo E, Wakefield RJ, et al. A systematic literature review analysis of ultrasound joint count and scoring systems to assess synovitis in rheumatoid arthritis according to the OMERACT filter. *J Rheumatol* 2011;38:2055-2062.
2. Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. *J Rheumatol* 2005;32:2485-2487.
3. Ellegaard K, Terslev L, Christensen R, et al. Comparison of discrimination and prognostic value of two US Doppler scoring systems in rheumatoid arthritis patients: a prospective cohort study. *Clin Exp Rheumatol* 2014;32:495-500.
4. Epis O, Scioscia C, Locaputo A, et al. Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy. *Clin Rheumatol* 2016;35:1923-1929.
5. Hau M, Kneitz C, Tony HP, et al. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). *Ann Rheum Dis* 2002;61:55-58.
6. Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Estimation of inflammation by Doppler ultrasound: quantitative changes after intra-articular treatment in rheumatoid arthritis. *Ann Rheum Dis* 2003;62:1049-1053.
7. Epis O, Filippucci E, Delle Sedie A, et al. Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series. *Rheumatol Int* 2014;34:737-742.

- 1  
2  
3 8. Rowbotham EL, Grainger AJ. Rheumatoid arthritis: ultrasound versus MRI. *Am J*  
4  
5 *Roentgenol* 2011;197:541-546.  
6
- 7 9. Hammer HB, Kvien TK. Comparisons of 7- to 78-joint ultrasonography scores: all  
8  
9 different joint combinations show equal response to adalimumab treatment in patients  
10  
11 with rheumatoid arthritis. *Arthritis Res Ther* 2011;13:R78.  
12
- 13 10. Filippucci E, Iagnocco A, Salaffi F, et al. Power Doppler sonography monitoring of  
14  
15 synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with  
16  
17 adalimumab. *Ann Rheum Dis* 2006;65:1433-1437.  
18
- 19 11. Perricone C, Ceccarelli F, Modesti M, et al. The 6-joint ultrasonographic assessment: a  
20  
21 valid, sensitive-to-change and feasible method for evaluating joint inflammation in RA.  
22  
23 *Rheumatology (Oxford)* 2012;51:866-73.  
24
- 25 12. Naredo E, Valor L, De la Torre I, et al. Ultrasound joint inflammation in rheumatoid  
26  
27 arthritis in clinical remission: how many and which joints should be assessed? *Arthritis*  
28  
29 *Care Res (Hoboken)* 2013;65:512-7.  
30
- 31 13. Naredo E, Rodriguez M, Campos C, et al. Validity, reproducibility, and responsiveness of  
32  
33 a twelve-joint simplified power doppler ultrasonographic assessment of joint  
34  
35 inflammation in rheumatoid arthritis. *Arthritis Rheum* 2008;59:515-22.  
36
- 37 14. Schmidt WA, Schicke B, Ostendorf B, et al. Low-field MRI versus ultrasound: which is  
38  
39 more sensitive in detecting inflammation and bone damage in MCP and MTP joints in  
40  
41 mild or moderate rheumatoid arthritis? *Clin Exp Rheumatol* 2013;31:91-96.  
42
- 43 15. Dougados M, Devauchelle-Pensec V, Ferlet JF, et al. The ability of synovitis to predict  
44  
45 structural damage in rheumatoid arthritis: a comparative study between clinical  
46  
47 examination and ultrasound. *Ann Rheum Dis* 2013;72:665-671.  
48
- 49 16. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid  
50  
51 arthritis patients with disease-modifying antirheumatic drug-induced clinical remission:  
52  
53  
54  
55  
56  
57  
58  
59  
60

- evidence from an imaging study may explain structural progression. *Arthritis Rheum* 2006;54:3761-3773.
17. Nguyen H, Ruysen-Witrand A, Gandjbakhch F, et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. *Rheumatology (Oxford)* 2014;53:2110-2118.
18. Bellis E, Scire CA, Carrara G, et al. Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. *Rheumatology (Oxford)* 2016;55:1826-1836.
19. Naredo E, Bonilla G, Gamero F, et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. *Ann Rheum Dis* 2005;64:375-381.
20. Mandl P, Balint PV, Brault Y, et al. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. *Arthritis Rheum* 2012;64:1272-1282.
21. Szkudlarek M, Terslev L, Wakefield RJ, et al. Summary Findings of a Systematic Literature Review of the Ultrasound Assessment of Bone Erosions in Rheumatoid Arthritis. *J Rheumatol* 2016;43:12-21.
22. Dougados M, Jousse-Joulin S, Mistretta F, et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. *Ann Rheum Dis* 2010;69:828-833.
23. Rosa J, Ruta S, Saucedo C, et al. Does a Simplified 6-Joint Ultrasound Index Correlate Well Enough With the 28-Joint Disease Activity Score to Be Used in Clinical Practice? *J Clin Rheumatol* 2016;22:179-183.

**Figure legends:**

Figure 1. Flowchart of the study population.

Figure 2: Examples of MCP joint grading: SH grade 3 and PD grade 2 (above), and SH grade 2 and PD grade 3 (below).

**Table 1-** Comparison between RA patient groups stratified based on their DAS 28 scores using the 22 joint US scoring system as detailed above (Kruskal-Wallis test,  $p < 0.05$  shows a significant difference between the patient groups).

RA patients stratified based on disease activity	DAS28 >5.1	DAS 28 3.2-5.1	DAS 28 2.6-3.2	DAS 28 <2.6	P value
Age Mean $\pm$ SD	55.6 $\pm$ 13.8	53.2 $\pm$ 16.	54.2 $\pm$ 15.5	50.3 $\pm$ 15.3	P=0.44
% Female	80.0	89.5	71.4	75.6	P=0.11
Disease duration (months): Mean $\pm$ SD	120.3 $\pm$ 107	111.7 $\pm$ 135	70.5 $\pm$ 58.4	95.4 $\pm$ 169.9	P=0.51
% of patients on steroids at the time of the scan (all patients were on $\leq$ 10 mg daily)	38	43.3	29.0	36.8	P=0.36
% of patients on conventional DMARDs at the time of the scan	74	54.2	64.5	65.8	P=0.11



% of patients on biologic treatment at the time of the scan	24	19.3	29.0	26.3	P=0.67
CRP Mean $\pm$ SD	8.2 $\pm$ 10.8	6.1 $\pm$ 14.8	4.3 $\pm$ 7.9	4.3 $\pm$ 9.6	P=0.42
ESR Mean $\pm$ SD	31.1 $\pm$ 26.7	16.4 $\pm$ 15.1	11.5 $\pm$ 15.5	6.8 $\pm$ 6.7	<b>P&lt;0.05</b>
SJC Mean $\pm$ SD	5.3 $\pm$ 4.6	2.4 $\pm$ 2.5	1.5 $\pm$ 1.9	0.5 $\pm$ 0.8	<b>P&lt;0.05</b>
TJC Mean $\pm$ SD	17.1 $\pm$ 7.5	6.7 $\pm$ 5.2	4.5 $\pm$ 4.6	1.3 $\pm$ 2.0	<b>P&lt;0.05</b>
GVAS Mean $\pm$ SD	74.6 $\pm$ 19.8	48.4 $\pm$ 26.4	34.4 $\pm$ 23.3	25 $\pm$ 26.2	<b>P&lt;0.05</b>
Mean DAS 28 score $\pm$ SD	5.9 $\pm$ 0.75	3.9 $\pm$ 0.5	2.9 $\pm$ 0.16	1.7 $\pm$ 0.6	<b>P&lt;0.05</b>
Total number of joints with SH grade 1 / patient Mean $\pm$ SD	2.4 $\pm$ 3.1	2.6 $\pm$ 3.7	1.7 $\pm$ 2.7	1.2 $\pm$ 1.8	P=0.52
Percentage of patients with joints with SH grade 1:	58.0	66.3	51.6	47.4	P=0.23
Total number of joints with SH grade 2 / patient Mean $\pm$ SD	2.4 $\pm$ 3.4	2.2 $\pm$ 3.2	1.6 $\pm$ 4.4	1.3 $\pm$ 2.5	P=0.36
Percentage of patients with joints with SH grade 2:	58.0	53.0	48.4	29.0	<b>P&lt;0.05</b>
Total number of joints with SH grade 3 / patient Mean $\pm$ SD	2.1 $\pm$ 2.8	1.2 $\pm$ 1.7	1.1 $\pm$ 2.1	0.7 $\pm$ 1.3	P=0.49
Percentage of patients with joints with SH grade 3:	52.0	44.6	35.5	31.6	P=0.23
PD score	1.9 $\pm$ 2.9	1.2 $\pm$ 2.4	1.1 $\pm$ 1.5	0.7 $\pm$ 1.3	P=0.58

Mean ± SD					
Percentage of patients with PD signal	58.0	42.2	45.2	36.8	P=0.19
Total number of joints with erosions / patient Mean ± SD	6.5 ± 7.3	5.0 ± 5.5	4.3 ± 3.8	2.7 ± 4.1	P=0.17
Percentage of patients with erosions:	64.0	49.4	64.5	39.5	P=0.09
Percentage of patients with tendon abnormalities (GS score ≥ 2)	8.16	10.4	13.3	10.81	P=0.42
Percentage of patients with active tenosynovitis (PD score ≥ 1)	6.12	5.81	8.13	10.81	P=0.13

**Table 2:** Comparison between 8 different US scores (P<0.05 was considered significant).

For Peer Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

US findings/scores	22 joints (wrists, MCPs, PIPs)	18 joints (wrists, MCP 2-5, PIP 2-5)	16 joints (MCP 2-5, PIP 2-5)	14 joints (wrists, MCP 2-4, PIP 2-4)	10 joints (wrists, MCP2-3, PIP 2-3)	8 joints (MCP2-3, PIP 2-3)	4 joints (wrists, MCP5)	4 joints (MCP 2-3 bilaterally)	P value
SH grade 2 score /patient	Median: 0 IQR: 3	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR: 1	Median: 0 IQR: 1	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR:1	-
Mean SH grade 2 score ± SD:	2 ± 3.21	1.19 ± 2.32	0.9 ± 1.83	0.71 ± 1.4	0.7 ± 1.39	0.15 ± 0.4	0.43 ± 0.92	1.19 ± 2.32	0.43
Percentage of patients with no evidence of SH grade 2:	51.8	64.3	64.3	66.5	69.6	69.6	89.3	76.8	0.15
SH grade 3 score /patient	Median: 0 IQR: 2	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR: 1	Median: 0 IQR: 1	Median: 0 IQR: 0	Median: 0 IQR: 0	-
Mean SH grade 3 score ± SD:	1.3 ± 2.08	0.71 ± 1.41	0.7 ± 1.40	0.58 ± 1.17	0.5 ± 0.97	0.5 ± 0.95	0.09 ± 0.34	0.35 ± 0.74	0.15
Percentage of patients with no evidence of SH grade 3:	57.1	69.2	69.2	71.4	74.1	74.1	93.3	77.7	0.15
PD score/patient	Median: 0 IQR: 2	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR: 0	-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Mean PD score $\pm$ SD:	1.28 $\pm$ 2.31	0.69 $\pm$ 1.68	0.66 $\pm$ 1.66	0.61 $\pm$ 1.39	0.48 $\pm$ 1.1	0.45 $\pm$ 1.07	0.09 $\pm$ 0.36	0.32 $\pm$ 0.76	0.15
Percentage of patients with well controlled hand RA (PD score = 0)	54.0	74.6	75.9	75.4	77.7	79.0	94.2	81.3	< 0.05
Percentage of patients misdiagnosed with well controlled disease by the simplified US scores	N/A	20.6	21.9	21.4	23.7	25	40.2	27.3	<0.05
Erosion score/patient	Median: 2 IQR: 7.75	Median: 1 IQR: 4	Median: 1 IQR: 4	Median: 1 IQR: 4	Median: 1 IQR: 3	Median IQR: 3	Median: 1 IQR: 1	Median: 1 IQR: 2	< 0.05
Percentage of patients with non-erosive hand RA:	30.4	42.4	42.4	46.9	46.9	46.9	68.8	55.4	< 0.05
Percentage of patients misdiagnosed with non-erosive hand RA by the	N/A	12	12	16.5	16.5	16.5	38.4	25	< 0.05

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

simplified US scores									
----------------------	--	--	--	--	--	--	--	--	--



For Peer Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



210x297mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



297x420mm (300 x 300 DPI)



Suppl. Table 1: Permutation correlations between pairs of US scoring systems assessing the total PD score (Spearman's correlation rank test,  $P < 0.05$  shows significant correlation).

Joints with PD	22 joints	18 joints (wrists + MCP 2-5, PIP 2-5)	16 joints (MCP 2-5, PIP 2-5)	14 joints (wrists + MCP 2-4, PIP 2-4)	10 joints (wrists MCP 2-3, PIP 2-3)	8 joints (MCP 2-3, PIP 2-3)	4 joints (wrists +MCP5)	4 joints (MCP 2-3 bilaterally)
4 joints (MCP 2-3)	$r = 0.64$ $P < 0.05$	$r = 0.85$ $P < 0.05$	$r = 0.87$ $P \leq 0.05$	$r = 0.87$ $P \leq 0.05$	$r = 0.91$ $P \leq 0.05$	$r = 0.94$ $P \leq 0.05$	$r = 0.29$ $P \leq 0.05$	-
4 joints (wrists, MCP5)	$r = 0.37$ $P \leq 0.05$	$r = 0.48$ $P \leq 0.05$	$r = 0.36$ $P \leq 0.05$	$r = 0.44$ $P \leq 0.05$	$r = 0.41$ $P \leq 0.05$	$r = 0.28$ $P \leq 0.05$	-	$r = 0.29$ $P \leq 0.05$
8 joints (MCP2-3, PIP 2-3)	$r = 0.68$ $P \leq 0.05$	$r = 0.90$ $P \leq 0.05$	$r = 0.93$ $P \leq 0.05$	$r = 0.92$ $P \leq 0.05$	$r = 0.96$ $P \leq 0.05$	-	$r = 0.28$ $P \leq 0.05$	$r = 0.94$ $P \leq 0.05$
10 joints (wrists, MCP 2- 3, PIP 2-3)	$r = 0.69$ $P \leq 0.05$	$r = 0.93$ $P < 0.05$	$r = 0.90$ $P \leq 0.05$	$r = 0.96$ $P \leq 0.05$	-	$r = 0.96$ $P \leq 0.05$	$r = 0.41$ $P \leq 0.05$	$r = 0.91$ $P \leq 0.05$
14 joints (wrists, + MCP 2-4, PIP 2-4)	$r = 0.72$ $P \leq 0.05$	$r = 0.98$ $P \leq 0.05$	$r = 0.95$ $P \leq 0.05$	-	$r = 0.96$ $P \leq 0.05$	$r = 0.92$ $P \leq 0.05$	$r = 0.44$ $P \leq 0.05$	$r = 0.87$ $P \leq 0.05$
16 joints (MCP 2-5, PIP 2-5)	$r = 0.73$ $P \leq 0.05$	$r = 0.97$ $P \leq 0.05$	-	$r = 0.95$ $P \leq 0.05$	$r = 0.90$ $P \leq 0.05$	$r = 0.93$ $P \leq 0.05$	$r = 0.36$ $P \leq 0.05$	$r = 0.87$ $P \leq 0.05$
18 joints (wrists + MCP 2-5, PIP 2-5)	$r = 0.74$ $P \leq 0.05$	-	$r = 0.97$ $P \leq 0.05$	$r = 0.98$ $P \leq 0.05$	$r = 0.93$ $P < 0.05$	$r = 0.90$ $P \leq 0.05$	$r = 0.48$ $P \leq 0.05$	$r = 0.85$ $P \leq 0.05$
22 joints	-	$r = 0.74$ $P \leq 0.05$	$r = 0.73$ $P \leq 0.05$	$r = 0.72$ $P \leq 0.05$	$r = 0.69$ $P \leq 0.05$	$r = 0.68$ $P \leq 0.05$	$r = 0.37$ $P \leq 0.05$	$r = 0.64$ $P \leq 0.05$

Suppl. Table 2: Permutation comparisons between pairs of US scoring related to their ability to detect the presence of PD signal ( $P < 0.05$  shows significant difference between scores).

Joints with PD	22 joints	18 joints (wrists, MCP 2-5, PIP 2-5)	16 joints ( MCP 2-5, PIP 2-5)	14 joints (wrists, MCP 2-4, PIP 2-4)	10 joints (wrists, MCP 2-3, PIP 2-3)	8 joints (MCP 2-3, PIP 2-3)	4 joints (wrists, MCP5)	4 joints (MCP 2-3 bilaterally)
4 joints (MCP 2-3)	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	-
4 joints (wrists + MCP5)	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	-	<b>P&lt;0.05</b>
8 joints (MCP2-3, PIP 2-3)	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	0.056	0.09	0.38	-	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
10 joints (wrists + MCP 2-3, PIP 2-3)	<b>P&lt;0.05</b>	0.059	0.09	0.14	-	0.38	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
14 joints (wrists + MCP 2-4, PIP 2-4)	<b>P&lt;0.05</b>	0.28	0.35	-	0.14	0.09	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
16 joints (MCP 2-5, PIP 2-5)	<b>P&lt;0.05</b>	0.42	-	0.35	0.09	0.056	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
18 joints (wrists + MCP 2-5, PIP 2-5)	<b>P&lt;0.05</b>	-	0.421	0.28	0.059	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
22 joints	-	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>

Suppl. Table 3: Permutation comparisons between pairs of US scoring related to their ability to detect moderate-severe SH (P<0.05 shows significant correlations).

Assessment of moderate-severe SH	22 joints	18 joints (wrists, MCP 2-5, PIP 2-5)	16 joints (MCP 2-5, PIP 2-5)	14 joints (wrists, MCP 2-4, PIP 2-4)	10 joints (wrists, MCP 2-3, PIP 2-3)	8 joints (MCP2-3, PIP 2-3)	4 joints (wrists, MCP5)	4 joints (MCP 2-3 bilaterally)
4 joints (MCP 2-3 bilaterally)	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	-
4 joints (wrists + MCP5)	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	-	<b>P&lt;0.05</b>
8 joints (MCP2-3, PIP 2-3)	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	P=0.077	P=0.91	-	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
10 joints (wrists + MCP 2-3, PIP 2-3)	<b>P&lt;0.05</b>	P=0.077	<b>P&lt;0.05</b>	P=0.096	-	P=0.91	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
14 joints (wrists + MCP 2-4, PIP 2-4)	<b>P&lt;0.05</b>	0.09	0.105	-	0.0967	0.077	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
16 joints (MCP 2-5, PIP 2-5)	<b>P&lt;0.05</b>	0.945	-	0.105	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
18 joints (wrists + MCP 2-5, PIP 2-5)	<b>P&lt;0.05</b>	-	0.945	0.0902	0.077	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>
22 joints	-	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>	<b>P&lt;0.05</b>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Diagnostic accuracy of simplified ultrasound hand examination protocols for detection of inflammation and disease burden in patients with rheumatoid arthritis**

Formatted: Line spacing: Double

Formatted: Font: 16 pt

**Abstract:**

Formatted: Font: 14 pt

**Background:** There is no consensus regarding the minimum of joints that should be included in an ultrasound (US) scoring system to reliably assess for disease activity in rheumatoid arthritis (RA).

**Purpose:** To assess whether simplified US protocols for hand examination are as informative as the examination of 22 joints in patients with RA, and to correlate the US parameters with disease activity (DAS-28).

**Material and Methods:** This is a cross-sectional study of 224 RA patients stratified based on their DAS-28 scores and assessed using eight preselected US examination protocols, including 22, 18, 16, 14, 10, 8 and two different combinations of 4 joints, respectively.

**Results:** We found a significant difference between different US hand scores regarding their ability to detect active inflammation and erosions. DAS-28 scores correlated very well with the Power Doppler (PD) scores generated by all eight US examination protocols ( $r=0.89-1$ ,

1  
2  
3  
4  
5  
6  
7 P<0.05), irrespective of patients' disease activity. Simplified US scores missed information  
8 on presence of PD in 20.6 - 40.2% patients (P<0.05), and misdiagnosed non-erosive hand RA  
9 in 12 - 38.4% patients (P<0.05), depending on the number of joints excluded from US hand  
10 examination.  
11  
12

13  
14  
15 **Conclusions:** Preselected simplified US scores are less reliable in appreciating the disease  
16 burden when compared with an extended protocol for 22 joint US examination, raising  
17 clinicians' awareness regarding the need to comprehensively assess multiple hand joints to  
18 reliably rule out subclinical inflammation.  
19  
20  
21

22  
23 **Keywords:** hand, ultrasound, Power Doppler ultrasound.  
24  
25  
26  
27

## 28 **Introduction**

Formatted: Font: 14 pt

29  
30  
31 RA is a chronic inflammatory condition associated with well-recognised inflammatory joint  
32 features, which are amenable to US examination. The use of US facilitated a significant  
33 progress in the early diagnosis of RA, enabling a better assessment of the disease activity,  
34 prognosis and response to different therapeutic interventions. The implementation of US  
35 scoring systems in addition to clinical examination could help standardising the way RA is  
36 monitored; however, based on local availability of US and sonographer expertise, different  
37 scoring systems have been used in clinical practice. Despite significant research progress in  
38 supporting the role of US in RA, no consensus was reached with regard to what scoring  
39 system is the most useful. The OMERACT US Task Force defined the US pathology  
40 associated with RA (1), which combines tendon, joint and bone abnormalities (1, 2). The  
41 presence of Power Doppler (PD) is recognized as a reliable objective measure of active joint  
42 inflammation (3). Different semi-quantitative scoring systems are currently used for  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 assessing synovial hypertrophy (SH), joint effusion, tendon abnormalities and erosions (4),  
8 and protocols for hand and feet US examination are well-established (5).  
9

10  
11 A recent systematic review of the scoring systems used to evaluate synovitis in RA found  
12 difficult to determine the least number of joints that needed to be assessed for a global US  
13 score (1). The purpose of our study was to investigate how much we can simplify the US  
14 examination of hands in RA, without compromising the ability of a certain US scoring  
15 system to evaluate the disease activity and damage associated with hand RA. The authors  
16 focused on the US examination of hands as this is the most commonly used in routine clinical  
17 practice.  
18  
19  
20  
21  
22  
23  
24

## 25 26 27 **Material and Methods:**

Formatted: Font: 14 pt

28  
29 This is a real-life, cross-sectional study, which evaluated patients referred to our US  
30 rheumatology outpatient clinics, presenting with inflammatory sounding hand joint pains.  
31  
32 The patients were referred based on clinician indication to have an US scan to help with  
33 identifying joint inflammation that was not confidently assessed clinically. We examined 604  
34 patients between Jan 2012 and August 2015. For each patient, a set of demographic, clinical  
35 and laboratory data were recorded at the time of the scan. Of 604 patients referred to our  
36 clinic, 224 patients with RA were included in the study analysis based on their final diagnosis  
37 made using the 2010 ACR/EULAR classification criteria, following complete investigations  
38 and revision of the clinical notes. Figure 1 details the patient selection and stratification  
39 based on DAS-28 scores.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 This study evaluated the same set of reported outcomes and clinical and laboratory  
51 parameters for all the patients, to ensure homogeneity of the collected data. The following  
52 information was analysed: disease duration (in months), hand tender joint count  
53  
54  
55

1  
2  
3  
4  
5  
6  
7 (TJC) and swollen joint count (SJC), as well as a patient reported global disease assessment  
8  
9 score (GVAS).

10  
11 | Additional data about the high sensitivity C-reactive protein (hsCRP), erythrocyte  
12  
13 sedimentation rate (ESR), presence of rheumatoid factor (RF), anti citrullinated cyclic  
14  
15 peptides antibodies (ACPA) and anti-nuclear antibodies (ANA) were collected at the time of  
16  
17 the scan (needed to exclude associated pathology).

18  
19 | For each patient, a detailed record was compiled of their medication at the time of the US  
20  
21 scan, including paracetamol and NSAIDs, disease-modifying drugs (DMARDs), biologic  
22  
23 therapies and glucocorticoids, either oral or intramuscular depot injection.

24  
25 | The US protocol examination used included the extensor tendons and 22 joint assessments  
26  
27 (dorsal longitudinal and transverse views of wrists, including extensor tendons, metacarpophalangeal – MCP joints, and proximal interphalangeal – PIP joints), as per our local clinic  
28  
29 protocol. The same US examination protocol was used for each patient, irrespective of their  
30  
31 hand symptoms. The US findings were scored according to the OMERACT scoring system  
32  
33 (1). The hand US examination was performed by two clinicians (CC and LA) in the same  
34  
35 session, and for each patient a consensus was obtained.

36  
37 | We used a Logiq S8 US machine (GE [Healthcare, Medical Systems US and Primary Care](#)  
38  
39 [Diagnostics](#), Wauwatosa, [Wisconsin](#), WI, USA), equipped with a multi-frequency linear  
40  
41 matrix array transducer (6-15 MHz). B-mode and PD machine setting were optimized and  
42  
43 standardized for all our patients' US examinations. The settings used were: B-mode frequency  
44  
45 11-15 MHz depending on the depth of the anatomical area, Doppler frequency 7.5-15,  
46  
47 depending on the depth of anatomical area; Doppler gain 18-20 dB, low wall filters and pulse  
48  
49 repetition frequency around 800 Hz. In this study, we only used Power Doppler (PD) mode.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Comment [AS1]: Is Wauwatosa correct??

Comment [AS2]:

Comment [CC3]: Yes, this is correct.

1  
2  
3  
4  
5  
6  
7 The information collected comprised the following US parameters: SH grade (graded 1-3),  
8 erosions (present/absent), PD signal (graded 1-3), joint effusion (present/absent), osteophytes  
9 (present/absent), and tendon abnormalities (PD signal present/absent) using the US definition  
10 of joint pathology as defined by the OMERACT group (2) (Fig. ~~ure~~ 2 exemplifies two MCP  
11 joints with different SH and PD grades). Well controlled disease was defined as PD score  
12 zero (including joints and tendons).  
13  
14  
15  
16  
17

18  
19 To address our research question and assess how many joints would require scanning, and  
20 which joints are most likely to provide the answer as to whether or not there is active disease,  
21 we tested and compared the following scoring systems (bilateral examination):  
22  
23  
24

- 25 - 22 joints (MCPs, PIPs, wrists)
- 26
- 27 - 18 joints (wrists, MCP 2-5 and PIP 2-5)
- 28
- 29 - 16 joints (MCP 2-5 and PIP 2-5)
- 30
- 31 - 14 joints (wrists, MCP 2-4 and PIP 2-4)
- 32
- 33 - 10 joints (wrists, MCP 2-3 and PIP 2-3)
- 34
- 35 - 8 joints (MCP 2-3 and PIP 2-3)
- 36
- 37 - 4 joints (wrists +MCP5)
- 38
- 39 - 4 joints (MCP 2-3)
- 40  
41

42 The above joint combination score was selected based on our experience of performing US  
43 examination of hands in more than 1000 patients, which identified that the most affected  
44 joints in RA were the wrists, MCP 2,3 and 5, and PIP 2 and 3 (unpublished observation).  
45  
46  
47

48  
49 The SH grade 1 score was calculated as the total number of the joints with SH grade 1, the  
50 SH grade 2 score as the total number of the joints with SH grade 2, and the SH grade 3 score  
51 as the total number of the joints with SH grade 3 per patient. The total PD score was the sum  
52  
53  
54  
55



1  
2  
3  
4  
5  
6  
7 of all individual PD scores per patient, and the erosion score was calculated as the total  
8 number of erosions per patient.  
9

10  
11 Data about active inflammation affecting tendons overlying the above mentioned joints were  
12 also collected and reported separately. The total grey scale scores and PD scores for joints  
13 were calculated as a sum of the individual scores for all the joints included in the US  
14 examination protocol the score refers to. The duration of the US examination was  
15 approximately 25 minutes/patient. This 22 joint protocol is used routinely in our US clinics,  
16 which have 30 minute slots for clinical and US examination of patients with RA.  
17

18  
19 Descriptive statistics were used to characterize the RA population, and Student T test, Mann-  
20 Whitney U and Kuskal-Wallis tests were implemented for the assessment of different  
21 parameters and US scoring systems (IBM SPSS Statistics 22, IBM Corporation, 1 New  
22 Orchard Road, Armonk, New York 10504-1722, US). A P-value of <0.05 was considered a  
23 statistically significant result. Spearman's correlation coefficients were used to correlate  
24 permutations of pairs of US scores and the total PD scores with the disease activity, as  
25 assessed by the disease activity score assessing 28 joints (DAS-28).  
26

27  
28 The data were collected as standard of practice. The study ~~analysed~~analyzed cross-sectionally  
29 the results of the US examinations of patients seen in our US clinics over a defined period of  
30 time. No ethical approval or patient's consent were required as no patient information was  
31 used for teaching or new intervention research. The results of our study analysis had no  
32 impact on the clinical management of patients and their confidentiality was maintained.  
33  
34  
35  
36

## 37 38 39 40 41 42 43 44 45 46 47 48 49 50 **Results:** 51 52 53 54 55 56 57 58 59 60

**Comment [AS4]:** All kind of commercial equipment, please give full name of the product, the producer and its location (city, state (if in the US) and country).

**Formatted:** Font: (Default) Times New Roman, 12 pt

**Formatted:** Font: 14 pt

1  
2  
3  
4  
5  
6  
7 To ~~characterise~~characterize in detail our RA cohort, we stratified patients based on DAS-28  
8 (ESR) assessment of disease activity (Table 1). Demographic parameters were similar among  
9 different disease activity groups. As expected, patients with higher disease activity scores had  
10 significantly higher TJC, SJC, ESR and GVAS, while the CRP levels were similar between  
11 different groups. Both objective and subjective parameters included in the DAS-28 composite  
12 score were significantly increased in patients with active disease compared to moderate or  
13 low disease activity groups and with the group in remission.  
14  
15  
16  
17  
18  
19

20  
21 There were no significant differences in the total US scores including the majority of US  
22 parameters, or in the disease duration or type of medication used (for both conventional and  
23 biologic DMARDs). The only significant difference was between the proportion of patients  
24 with SH grade 2 at the US examination of their hands, which was higher in patients with  
25 moderately-active and strongly-active RA ( $P<0.05$ ) (Table 1). The SH grade 2 total score also  
26 correlated with the SJC ( $r=0.89$ ,  $P<0.05$ ).  
27  
28  
29  
30  
31

32  
33 The comparative analyse of the above-mentioned US scores showed no significant  
34 differences between the ability of the pre-selected US scores to capture information regarding  
35 SH grade 2 and 3, and the total PD scores per patient; however, the proportion of patients  
36 with no active disease at the US examination differed significantly based on the number of  
37 joints included in the examination protocol ( $P<0.05$ ) (Table 2). Similarly, different US scores  
38 varied significantly in their ability to assess the total erosion score per patient and the  
39 proportion of patients with erosions ( $P<0.05$ ). By simplifying the US examination of the hand  
40 in RA patients, active RA was underdiagnosed in a proportion of 20.6 to 40.2% of patients;  
41  
42  
43  
44  
45  
46  
47 similarly, the erosive burden was underappreciated in 12 - 28.4% RA patients (Table 2).  
48  
49

50  
51 Strong correlations were found between the PD score generated by the 22 joint examination  
52 and all of the other US score combinations ( $r = 0.68 - 0.74$ ,  $P<0.05$ ). The scores that  
53  
54  
55

1  
2  
3  
4  
5  
6  
7 correlated very strongly were those assessing 8, 10 and 14 joints ( $r = 0.92-0.96$ ,  $P < 0.05$ ). The  
8  
9 weakest correlation was found between the 8 and the 4 joint score (wrist and MCP 5  
10 bilaterally) ( $r=0.28$ ,  $P < 0.05$ ) (Suppl. Table 1).  
11

12  
13 The permutation comparisons between pairs of US scores related to their ability to detect the  
14 presence active joint inflammation found no significant differences between the total PD  
15 scores assessed by 8, 10, 12 and 16 joint US scores and 10, 12, 16 and 18 joint scores,  
16  
17 respectively (Suppl. Table 2). Similarly, the total grey scale score (combining the total scores  
18  
19 for SH grade 2 and 3) identified no significant differences between the permutation  
20  
21 comparisons between the scores assessing 8, 10, 14, 16 and 18 joints (Suppl. Table 3).  
22  
23  
24

25 The analysis was also focused on correlating the total PD scores derived from all the pre-set  
26  
27 US examination protocols with the DAS-28 scores in patients stratified based on their disease  
28  
29 activity, to identify if certain US hand examination protocols can be used differentially in  
30  
31 patients with active disease compared to patients in remission. All the total PD scores derived  
32  
33 from the eight US examination protocols correlated very strongly with DAS-28 assessment,  
34  
35 irrespective of how well the disease was controlled ( $r = 0.88-1$ ,  $P < 0.005$ ).  
36  
37

## 38 39 Discussion

40  
41  
42 ~~In conclusion,~~ This is the first large cross-sectional study correlating different US  
43  
44 examination protocols (derived from a 22-hand joint comprehensive score) with DAS-28  
45  
46 score in patients in RA, stratified based on their disease activity.  
47

48  
49 Quantitative and semi-quantitative US scores have been previously compared in RA (3), and  
50  
51 US examination have been found to be sensitive to therapeutic interventions (4-8). A  
52  
53 comprehensive study comparing several US score systems in RA found that all were sensitive  
54  
55

1  
2  
3  
4  
5  
6  
7 to change when assessing the response of RA patients to adalimumab (9, 10). In addition,  
8 simplified US scores (including 6 or 12 joints) have previously been compared with extensive  
9 US protocol examinations (assessing 12, and 44 joints respectively), and showed good  
10 sensitivity to change in three separate studies (11-13). However, none of these studies  
11 stratified patients based on their disease activity scores or included RA patients based on the  
12 clinical indication to have an US scan, as it is the case with our study. The need to use a  
13 comprehensive US scoring system, capturing both active and chronic inflammatory changes  
14 for assessment of RA disease activity, is supported by the good correlation between US and  
15 MRI findings (8, 14). The presence of SH and PD signal was found to be associated with  
16 structural damage in RA (15), even in patients in clinical remission (16), and was associated  
17 with risk of flares (17, 18). ~~There was a good correlation between US findings and clinical~~  
18 ~~examination in one study examining 60 joints/patient (19); however, there are obvious~~  
19 ~~limitations to implement in practice such a comprehensive US protocol.~~

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 The role and reliability of US in the disease activity assessment in patients with RA is  
33 supported by several studies (19-21). ~~It was previously proposed that a targeted US~~  
34 ~~remission in early RA would inform clinicians better about the need of disease control~~  
35 ~~optimisationoptimization compared to clinical assessment; however, this was not associated~~  
36 ~~with long term benefits in a recent randomisedrandomized controlled trial (22).~~

37  
38  
39  
40  
41  
42 Previous studies reported good correlation between hand US scores and DAS-28 assessment  
43 using three different US scores (23, 24), result that was also replicated by our study, which  
44 included a larger number of joint combinations, and also assessed US parameters stratified  
45 based on the DAS-28 scores.

46  
47  
48  
49  
50  
51 Our comparative analysis of several US scoring systems showed that there is significant  
52 difference in terms of the equivalence of several US hand-scoring systems. ~~that can be used~~

1  
2  
3  
4  
5  
6  
7 ~~in routine practice.~~ Our study found that age, duration of symptoms, duration of disease, type  
8 of medication and total PD score generated by US examination of hands were not able to  
9 inform about the inclusion of patients in one specific disease activity group, as patients  
10 stratified based on DAS 28 scores had similar parameters. ~~Only the proportion of patients~~  
11 ~~with joints with SH grade 2 was different across different disease activity groups; however,~~  
12 ~~this finding was not replicated in the case of severe SH (grade 3), disparity that can be~~  
13 ~~explained by the lower number of patients with SH grade 3 included in our study.~~

14  
15  
16  
17  
18  
19  
20  
21 In addition to previous studies, we have been interested in exploring the amount and  
22 significance of missed information related to the use of simplified US hand examination  
23 protocols. A significant proportion of patients have been diagnosed as having well-controlled  
24 or non-erosive hand RA ~~in our study~~ by using US protocols limiting the number of joints  
25 examined (10.6 - 40.2 % and 12-34.8%, respectively). Our study found that the assessment  
26 of our preselected 8, 10 and 14 joints captured comparable amounts of information regarding  
27 disease activity in RA (still misdiagnosing around 40% of patients as having well controlled  
28 disease, equivalent to PD score zero), while the two 4 joint scores missed significant  
29 information when compared to the others (around 60% patient were diagnosed in remission  
30 despite having active disease at least in one joint). The scores including 20 and 22 joints  
31 captured more information than the 8, 10 and 14 joint scores, even if all the eight US scores  
32 we explored correlated very well with the DAS-28 assessment. This is particularly relevant  
33 for our patient group, characterized by a small number of active joints and clinical indication  
34 to have an US scan to establish if their disease was well controlled or not. In this context,  
35 underdiagnosing active disease would have erroneously led to classifying our patients as  
36 being in remission. The clinical consensus is that we cannot predict which joints are the most  
37 likely to flare in patients with RA patients; therefore examining only the joints that previously  
38 flared using a patient-tailored US protocol is not justified.

1  
2  
3  
4  
5  
6  
7 ~~In conclusion,~~ Even if a comprehensive hand joint score is time-consuming, it can provide  
8 significant additional information compared to a simplified score, as our study showed. As  
9 expected, all the scores correlated very well with each other, because they are derived from a  
10 comprehensive US hand score, while missing significant information proportional to the  
11 number of joints excluded from US examination. All the pre-selected US hand scores  
12 correlated with the disease activity scores, despite the fact that the patient groups stratified  
13 based on disease activity had similar median total PD scores. This showed that subclinical in  
14 inflammation can be found in similar proportion in RA patients, irrespective of their degree of  
15 chronic joint changes that are likely to influence their DAS-28 score.

24 Limitations: Our study did not have strict inclusion criteria: the patients were included based  
25 on clinical indication to exclude subclinical synovitis. Therefore, there is a significant  
26 selection bias, as the study did not capture patients with obvious active synovitis detected by  
27 clinical examination. In this particular clinical context, detection of active disease in at least  
28 one joint is clinically relevant, as US examination triggered treatment optimization to  
29 minimize joint damage (e.g. guided steroid injection targeting the active joints or escalation  
30 of therapy).

38 In conclusion, ~~Our study concluded that~~ even if simplified US scores for hand assessment of  
39 RA disease activity can be useful in practice, by examining additional joints, clinicians are  
40 able to detect subclinical inflammation, which is not captured by the simplified US scores. If  
41 previously studies re-assured clinicians that various US examination protocols correlated well  
42 with the DAS-28 assessment or were sensitive to change following therapy, our study showed  
43 that a significant proportion of patients can be misclassified as having well-controlled or non-  
44 erosive disease as a result of simplified US protocols. Further studies, including large  
45 longitudinal cohorts, are needed to establish the smaller number of joints needed to be

1  
2  
3  
4  
5  
6  
7 examined to ~~minimise~~minimize the risk of under detecting subclinical inflammation in  
8 patients with hand RA.  
9

#### 10 11 **Conflict of interest:**

12  
13 The authors declared no conflicts of interest.  
14

#### 15 16 **Funding**

17  
18  
19  
20 ~~This research did not receive any specific grant from funding agencies in the public,~~  
21 ~~commercial, or not-for-profit sectors. CC was funded by a Biomedical Research Council~~  
22 ~~Funding grant – BRC/H/001.~~  
23  
24

Comment [C5]: The details about funding were transferred to the title page, as required.

- 25  
26  
27  
28  
29  
30 1. Mandl P, Naredo E, Wakefield RJ, et al. A systematic literature review analysis of  
31 ultrasound joint count and scoring systems to assess synovitis in rheumatoid arthritis  
32 according to the OMERACT filter. J Rheumatol 2011;38:2055-2062.  
33  
34  
35  
36 2. Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including  
37 definitions for ultrasonographic pathology. J Rheumatol. 2005;32:2485-2487.  
38  
39  
40 3. Ellegaard K, Terslev L, Christensen R, et al. Comparison of discrimination and  
41 prognostic value of two US Doppler scoring systems in rheumatoid arthritis patients: a  
42 prospective cohort study. Clin Exp Rheumatol. 2014;32:495-500.  
43  
44  
45 4. Epis O, Scioscia C, Locaputo A, et al. Use of ultrasound in treatment decisions for  
46 patients with rheumatoid arthritis: an observational study in Italy. Clin Rheumatol.  
47 2016;35:1923-1929.  
48  
49  
50 5. Hau M, Kneitz C, Tony HP, et al. High resolution ultrasound detects a decrease in pannus  
51 vascularisation of small finger joints in patients with rheumatoid arthritis receiving  
52  
53  
54

- 1  
2  
3  
4  
5  
6  
7 [treatment with soluble tumour necrosis factor alpha receptor \(etanercept\). Ann Rheum](#)  
8 [Dis. 2002;61:55-58.](#)  
9  
10  
11 6. [Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Estimation of inflammation by Doppler](#)  
12 [ultrasound: quantitative changes after intra-articular treatment in rheumatoid arthritis.](#)  
13 [Ann Rheum Dis. 2003;62:1049-1053.](#)  
14  
15  
16 7. [Epis O, Filippucci E, Delle Sedie A, et al. Clinical and ultrasound evaluation of the](#)  
17 [response to tocilizumab treatment in patients with rheumatoid arthritis: a case series.](#)  
18 [Rheumatol Int. 2014;34:737-742.](#)  
19  
20  
21 8. [Rowbotham EL, Grainger AJ. Rheumatoid arthritis: ultrasound versus MRI. Am J](#)  
22 [Roentgenol. 2011;197:541-546.](#)  
23  
24  
25 9. [Hammer HB, Kvien TK. Comparisons of 7- to 78-joint ultrasonography scores: all](#)  
26 [different joint combinations show equal response to adalimumab treatment in patients](#)  
27 [with rheumatoid arthritis. Arthritis Res Ther. 2011;13:R78.](#)  
28  
29  
30 10. [Filippucci E, Iagnocco A, Salaffi F, et al. Power Doppler sonography monitoring of](#)  
31 [synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with](#)  
32 [adalimumab. Ann Rheum Dis. 2006;65:1433-1437.](#)  
33  
34  
35 11. [Perricone C, Ceccarelli F, Modesti M, et al. The 6-joint ultrasonographic assessment: a](#)  
36 [valid, sensitive-to-change and feasible method for evaluating joint inflammation in RA.](#)  
37 [Rheumatology \(Oxford\). 2012;51:866-73.](#)  
38  
39  
40 12. [Naredo E, Valor L, De la Torre I, et al. Ultrasound joint inflammation in rheumatoid](#)  
41 [arthritis in clinical remission: how many and which joints should be assessed? Arthritis](#)  
42 [Care Res \(Hoboken\). 2013;65:512-7.](#)  
43  
44  
45 13. [Naredo E, Rodriguez M, Campos C, et al. Validity, reproducibility, and responsiveness of](#)  
46 [a twelve-joint simplified power doppler ultrasonographic assessment of joint](#)  
47 [inflammation in rheumatoid arthritis. Arthritis Rheum. 2008;59:515-22.](#)  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
14. Schmidt WA, Schicke B, Ostendorf B, et al. Low-field MRI versus ultrasound: which is more sensitive in detecting inflammation and bone damage in MCP and MTP joints in mild or moderate rheumatoid arthritis? Clin Exp Rheumatol. 2013;31:91-96.
15. Dougados M, Devauchelle-Pensec V, Ferlet JF, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis. 2013;72:665-671.
16. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761-3773.
17. Nguyen H, Ruysse-Witrand A, Gandjibakhch F, et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53:2110-2118.
18. Bellis E, Scire CA, Carrara G, et al. Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. Rheumatology (Oxford). 2016;55:1826-1836.
19. Naredo E, Bonilla G, Gamero F, et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis. 2005;64:375-381.
20. Mandl P, Balint PV, Brault Y, et al. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. Arthritis Rheum. 2012;64:1272-1282.

21. [Szkudlarek M, Terslev L, Wakefield RJ, et al. Summary Findings of a Systematic Literature Review of the Ultrasound Assessment of Bone Erosions in Rheumatoid Arthritis. J Rheumatol. 2016;43:12-21.](#)
22. [Dougados M, Jousse-Joulin S, Mistretta F, et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis. 2010;69:828-833.](#)
23. [Rosa J, Ruta S, Saucedo C, et al. Does a Simplified 6-Joint Ultrasound Index Correlate Well Enough With the 28-Joint Disease Activity Score to Be Used in Clinical Practice? J Clin Rheumatol. 2016;22:179-183.](#)

#### Figure legends:

[Figure 1. Flowchart of the study population.](#)

[Figure 2: Examples of MCP joint grading: SH grade 3 and PD grade 2 \(above\), and SH grade 2 and PD grade 3 \(below\)](#)

#### References:

1. Mandl P, Naredo E, Wakefield RJ, Conaghan PG, D'Agostino MA, Force OUT. A systematic literature review analysis of ultrasound joint count and scoring systems to assess synovitis in rheumatoid arthritis according to the OMERACT filter. J Rheumatol. 2011;38(9):2055-62.
2. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005;32(12):2485-7.
3. Ellegaard K, Terslev L, Christensen R, Szkudlarek M, Schmidt WA, Jensen PS, et al. Comparison of discrimination and prognostic value of two US Doppler scoring systems in rheumatoid arthritis patients: a prospective cohort study. Clin Exp Rheumatol. 2014;32(4):495-500.

Formatted: Indent: Left: 0"

Formatted: Font: Times New Roman, 12 pt

Formatted: Line spacing: Double

Formatted: Font: 14 pt

Formatted: Line spacing: Double

4. Epis O, Scioscia C, Locaputo A, Cappelli A, Maier A, Rocchetta PA, et al. Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy. *Clin Rheumatol*. 2016;35(8):1923-9.
5. Hau M, Kneitz C, Tony HP, Keberle M, Jahns R, Jenett M. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). *Ann Rheum Dis*. 2002;61(1):55-8.
6. Terslev L, Torp-Pedersen S, Qvistgaard E, Danneskiold-Samsøe B, Bliddal H. Estimation of inflammation by Doppler ultrasound: quantitative changes after intra-articular treatment in rheumatoid arthritis. *Ann Rheum Dis*. 2003;62(11):1049-53.
7. Epis O, Filippucci E, Delle Sedie A, De Matthaeis A, Bruschi E. Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series. *Rheumatol Int*. 2014;34(5):737-42.
8. Rowbotham EL, Grainger AJ. Rheumatoid arthritis: ultrasound versus MRI. *AJR Am J Roentgenol*. 2011;197(3):541-6.
9. Hammer HB, Kvien TK. Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2011;13(3):R78.
10. Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. *Ann Rheum Dis*. 2006;65(11):1433-7.
11. Perricone C, Ceccarelli F, Modesti M, Vavala C, Di-Franco M, Valesini G, et al. The 6-joint ultrasonographic assessment: a valid, sensitive to change and feasible method for evaluating joint inflammation in RA. *Rheumatology (Oxford)*. 2012;51(5):866-73.
12. Naredo E, Valor L, De la Torre I, Martinez-Barrio J, Hinojosa M, Aramburu F, et al. Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed? *Arthritis Care Res (Hoboken)*. 2013;65(4):512-7.
13. Naredo E, Rodriguez M, Campos C, Rodriguez-Heredia JM, Medina JA, Giner E, et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. *Arthritis Rheum*. 2008;59(4):515-22.
14. Schmidt WA, Schicke B, Ostendorf B, Scherer A, Krause A, Walther M. Low field MRI versus ultrasound: which is more sensitive in detecting inflammation and bone damage in MCP and MTP joints in mild or moderate rheumatoid arthritis? *Clin Exp Rheumatol*. 2013;31(1):91-6.
15. Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D'Agostino MA, Backhaus M, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. *Ann Rheum Dis*. 2013;72(5):665-71.
16. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease modifying antirheumatic drug induced clinical remission: evidence from an imaging study may explain structural progression. *Arthritis Rheum*. 2006;54(12):3761-73.
17. Nguyen H, Ruysse Witrand A, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. *Rheumatology (Oxford)*. 2014;53(11):2110-8.
18. Bellis E, Scire CA, Carrara G, Adinolfi A, Batticciotto A, Bortoluzzi A, et al. Ultrasound detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. *Rheumatology (Oxford)*. 2016;55(10):1826-36.

19. ~~Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis. 2005;64(3):375-81.~~
20. ~~Mandl P, Balint PV, Brault Y, Backhaus M, D'Agostino MA, Grassi W, et al. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. Arthritis Rheum. 2012;64(4):1272-82.~~
21. ~~Szkudlarek M, Terslev L, Wakefield RJ, Backhaus M, Balint PV, Bruyn GA, et al. Summary Findings of a Systematic Literature Review of the Ultrasound Assessment of Bone Erosions in Rheumatoid Arthritis. J Rheumatol. 2016;43(1):12-21.~~
22. ~~Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M, et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016;75(6):1043-50.~~
23. ~~Dougados M, Jousse Joulin S, Mistretta F, d'Agostino MA, Backhaus M, Bentin J, et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis. 2010;69(5):828-33.~~
24. ~~Rosa J, Ruta S, Saucedo C, Navarta DA, Catoggio LJ, Garcia-Monaco R, et al. Does a Simplified 6-Joint Ultrasound Index Correlate Well Enough With the 28-Joint Disease Activity Score to Be Used in Clinical Practice? J Clin Rheumatol. 2016;22(4):179-83.~~

Formatted: Line spacing: Double

Table 1- Comparison between RA patient groups stratified based on their DAS 28 scores using the 22 joint US scoring system as detailed above (Kruskal-Wallis test, p<0.05 shows a significant difference between the patient groups).

RA patients stratified based on disease activity	DAS28 >5.1	DAS 28 3.2-5.1	DAS 28 2.6-3.2	DAS 28 <2.6	P value
Age Mean $\pm$ SD	55.6 $\pm$ 13.8	53.2 $\pm$ 16.	54.2 $\pm$ 15.5	50.3 $\pm$ 15.3	P=0.44
% Female	80.0	89.5	71.4	75.6	P=0.11
Disease duration (months): Mean $\pm$ SD	120.3 $\pm$ 107	111.7 $\pm$ 135	70.5 $\pm$ 58.4	95.4 $\pm$ 169.9	P=0.51
% of patients on steroids at the time of the scan (all patients were on $\leq$ 10 mg daily)	38	43.3	29.0	36.8	P=0.36
% of patients on conventional DMARDs at the time of the scan	74	54.2	64.5	65.8	P=0.11

<u>% of patients on biologic treatment at the time of the scan</u>	<u>24</u>	<u>19.3</u>	<u>29.0</u>	<u>26.3</u>	<u>P=0.67</u>
<u>CRP</u> <u>Mean ± SD</u>	<u>8.2 ± 10.8</u>	<u>6.1 ± 14.8</u>	<u>4.3 ± 7.9</u>	<u>4.3 ± 9.6</u>	<u>P=0.42</u>
<u>ESR</u> <u>Mean ± SD</u>	<u>31.1 ± 26.7</u>	<u>16.4 ± 15.1</u>	<u>11.5 ± 15.5</u>	<u>6.8 ± 6.7</u>	<u>P&lt;0.05</u>
<u>SJC</u> <u>Mean ± SD</u>	<u>5.3 ± 4.6</u>	<u>2.4 ± 2.5</u>	<u>1.5 ± 1.9</u>	<u>0.5 ± 0.8</u>	<u>P&lt;0.05</u>
<u>TJC</u> <u>Mean ± SD</u>	<u>17.1 ± 7.5</u>	<u>6.7 ± 5.2</u>	<u>4.5 ± 4.6</u>	<u>1.3 ± 2.0</u>	<u>P&lt;0.05</u>
<u>GVAS</u> <u>Mean ± SD</u>	<u>74.6 ± 19.8</u>	<u>48.4 ± 26.4</u>	<u>34.4 ± 23.3</u>	<u>25 ± 26.2</u>	<u>P&lt;0.05</u>
<u>Mean DAS 28 score ± SD</u>	<u>5.9 ± 0.75</u>	<u>3.9 ± 0.5</u>	<u>2.9 ± 0.16</u>	<u>1.7 ± 0.6</u>	<u>P&lt;0.05</u>
<u>Total number of joints with SH grade 1 / patient</u> <u>Mean ± SD</u>	<u>2.4 ± 3.1</u>	<u>2.6 ± 3.7</u>	<u>1.7 ± 2.7</u>	<u>1.2 ± 1.8</u>	<u>P=0.52</u>
<u>Percentage of patients with joints with SH grade 1:</u>	<u>58.0</u>	<u>66.3</u>	<u>51.6</u>	<u>47.4</u>	<u>P=0.23</u>
<u>Total number of joints with SH grade 2 / patient</u> <u>Mean ± SD</u>	<u>2.4 ± 3.4</u>	<u>2.2 ± 3.2</u>	<u>1.6 ± 4.4</u>	<u>1.3 ± 2.5</u>	<u>P=0.36</u>
<u>Percentage of patients with joints with SH grade 2:</u>	<u>58.0</u>	<u>53.0</u>	<u>48.4</u>	<u>29.0</u>	<u>P&lt;0.05</u>
<u>Total number of joints with SH grade 3 / patient</u> <u>Mean ± SD</u>	<u>2.1 ± 2.8</u>	<u>1.2 ± 1.7</u>	<u>1.1 ± 2.1</u>	<u>0.7 ± 1.3</u>	<u>P=0.49</u>
<u>Percentage of patients with joints with SH grade 3:</u>	<u>52.0</u>	<u>44.6</u>	<u>35.5</u>	<u>31.6</u>	<u>P=0.23</u>
<u>PD score</u> <u>Mean ± SD</u>	<u>1.9 ± 2.9</u>	<u>1.2 ± 2.4</u>	<u>1.1 ± 1.5</u>	<u>0.7 ± 1.3</u>	<u>P=0.58</u>

Percentage of patients with PD signal	<u>58.0</u>	<u>42.2</u>	<u>45.2</u>	<u>36.8</u>	<u>P=0.19</u>
Total number of joints with erosions / patient Mean $\pm$ SD	<u>6.5 <math>\pm</math> 7.3</u>	<u>5.0 <math>\pm</math> 5.5</u>	<u>4.3 <math>\pm</math> 3.8</u>	<u>2.7 <math>\pm</math> 4.1</u>	<u>P=0.17</u>
Percentage of patients with erosions:	<u>64.0</u>	<u>49.4</u>	<u>64.5</u>	<u>39.5</u>	<u>P=0.09</u>
Percentage of patients with tendon abnormalities (GS score $\geq$ 2)	<u>8.16</u>	<u>10.4</u>	<u>13.3</u>	<u>10.81</u>	<u>P=0.42</u>
Percentage of patients with active tenosynovitis (PD score $\geq$ 1)	<u>6.12</u>	<u>5.81</u>	<u>8.13</u>	<u>10.81</u>	<u>P=0.13</u>

Table 2: Comparison between 8 different US scores (P<0.05 was considered significant).

US findings/ scores	22 joints	18 joints	16 joints	14 joints	10 joints	8 joints	4 joints	4 joints	* P value
	(wrists, MCPs, PIPs)	(wrists, MCP 2-5, PIP 2-5)	(MCP 2-5, PIP 2-5)	(wrists, MCP 2-4, PIP 2-4)	(wrists, MCP2-3, PIP 2-3)	(MCP2-3, PIP 2-3)	(wrists, MCP5)	(MCP 2-3 bilaterally)	Formatted Table
SH grade 2 score /patient	Median: 0 IQR: 3	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR: 1	Median: 0 IQR: 1	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR:1	=
Mean SH grade 2 score ± SD	2 ± 3.21	1.19 ± 2.32	0.9 ± 1.83	0.71 ± 1.4	0.7 ± 1.39	0.15 ± 0.4	0.43 ± 0.92	1.19 ± 2.32	0.43
Percentage of patients with no evidence of SH grade 2:	51.8	64.3	64.3	66.5	69.6	69.6	89.3	76.8	0.15
SH grade 3 score /patient	Median: 0 IQR: 2	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR: 1	Median: 0 IQR: 1	Median: 0 IQR: 0	Median: 0 IQR: 0	=
Mean SH grade 3 score ± SD	1.3 ± 2.08	0.71 ± 1.41	0.7 ± 1.40	0.58 ± 1.17	0.5 ± 0.97	0.5 ± 0.95	0.09 ± 0.34	0.35 ± 0.74	0.15
Percentage of patients with no evidence of SH grade 3:	57.1	69.2	69.2	71.4	74.1	74.1	93.3	77.7	0.15
PD score/patient	Median: 0 IQR: 2	Median: 0 IQR:1	Median: 0 IQR:1	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR: 0	Median: 0 IQR: 0	=
Mean PD score ± SD:	1.28 ± 2.31	0.69 ± 1.68	0.66 ± 1.66	0.61 ± 1.39	0.48 ± 1.1	0.45 ± 1.07	0.09 ± 0.36	0.32 ± 0.76	0.15
Percentage of patients with well controlled hand RA (PD score = 0)	54.0	74.6	75.9	75.4	77.7	79.0	94.2	81.3	< 0.05
Percentage of patients misdiagnosed with well controlled disease by the simplified US scores	N/A	20.6	21.9	21.4	23.7	25	40.2	27.3	< 0.05
Erosion score/patient	Median: 2 IQR: 7.75	Median: 1 IQR: 4	Median: 1 IQR: 4	Median: 1 IQR: 4	Median: 1 IQR: 3	Median: 1 IQR: 3	Median: 1 IQR: 1	Median: 1 IQR: 2	< 0.05

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only

Percentage of patients with non-erosive hand RA:	<u>30.4</u>	<u>42.4</u>	<u>42.4</u>	<u>46.9</u>	<u>46.9</u>	<u>46.9</u>	<u>68.8</u>	<u>55.4</u>	<u>&lt; 0.05</u>
Percentage of patients misdiagnosed with non-erosive hand RA by the simplified US scores	<u>N/A</u>	<u>12</u>	<u>12</u>	<u>16.5</u>	<u>16.5</u>	<u>16.5</u>	<u>38.4</u>	<u>25</u>	<u>&lt; 0.05</u>

Formatted: Line spacing: Double

Formatted: Font: Times New Roman, 12 pt